ALSO NOTED: Amgen analysts bearish; FDA hands Kyowa not-approvable letter; Valeant plans review; and much more...

> Oh, the curse of duplication. Schering-Plough embarked on a company-wide downsizing yesterday, eliminating hundreds of jobs in nearly all departments, including finance, research, information technology, and marketing. Report

> Faced with what they see as the likelihood of some significant restrictions on the use of Amgen's anemia drugs--as well as new data on risks associated with the drugs--analysts have been turning distinctly bearish on the biotech giant's stock. Report

> Kyowa Pharmaceutical has received a not-approvable letter from the FDA for istradefylline (KW-6002), its investigational drug for the treatment of Parkinson's disease. Release

> Valeant Pharmaceuticals says it will undertake a strategic review after reporting weak results for the fourth quarter. Release

> The U.S. Patent office has upheld the validity of Geron's patent for human embryonic stem cells. Report

> Any attempt to track down the source of problems with the blood thinner heparin are likely to run into trouble following a convoluted supply trail in China. Report

> The FDA has nixed Eli Lilly's plans for a long-acting formulation of its antipsychotic Zyprexa. Report

> GSK's secret vaccine adjuvant is drawing attention. Report

And Finally... The CDC has greatly expanded the population of people it's recommending for an annual flu shot, saying everyone aged six months to 18 should get the an annual jab. Report

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.